Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15382502 | 0.94 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL3636729 | 0.94 | ALDH1A1 (0.56) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL8547307 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL8547303 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL510213 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL8547301 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL8550317 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL4058730 | 0.90 | HPGD (0.56) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL510687 | 0.90 | HPGD (0.56) | ALDH1A1KDM4ECYP2A6PTPN1FAAH | |
| SCHEMBL209319 | 0.87 | HRH1 (0.59) | ALDH1A1KDM4ECYP2A6PTPN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700019-A1 | CRYSTAL FORM OF 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE CITRATE, PREPARATION METHOD, AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| WO-2025132943-A1 | DECAHYDROQUINOLINES AS DNA POLYMERASE THETA INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024217521-A1 | CRYSTAL FORM OF 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE CITRATE, PREPARATION METHOD, AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| EP-4392422-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103368-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116969959-A | Substituted tetrahydroquinoline derivative and application thereof | 浙江大学 | 2023-10-31 | — | — | CN | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | ALDH1A1 298/4885KDM4E 551/4885CYP2A6 214/4885 |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885KDM4E 710/4885CYP2A6 4756/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | ALDH1A1 75/4885KDM4E 4414/4885CYP2A6 31/4885 |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | NAT1, POLM, PYGL | ALDH1A1 1657/4885KDM4E 4018/4885CYP2A6 199/4885 |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885KDM4E 710/4885CYP2A6 4756/4885 |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885KDM4E 710/4885CYP2A6 4756/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | ALDH1A1 75/4885KDM4E 4414/4885CYP2A6 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.